powered by cea

STRONGERTOGETHER

Provided by a partnership between the American Society for Clinical Pathology and Clinical Care Options, LLC

Optimal Utilization of Ki67 Testing in HR-Positive/ HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams

Saturday, September 10, 2022 | 3:10 PM
GLAONS 6th Annual Oncology Care Summit
Los Angeles, CA



This activity is supported by an educational grant from Lilly.

Program Chairs

Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Sara Tolaney, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Women's Cancer
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Faculty

Adam M. Brufsky, MD, PhD
Professor of Medicine
Hematology/Oncology
University of Pittsburgh School of Medicine
Associate Chief, Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Susan Dent, MD, FRCPC
Professor of Medicine
School of Medicine/Division of Medical Oncology
Duke University
Durham, North Carolina

Faculty

Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Research Program
Drug Development Unit
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee

Sara Hurvitz, MD, FACP
Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Faculty

Komal Jhaveri, MD, FACP
Assistant Professor of Medicine
Weill Cornell Medical College
Associate Attending Physician
Breast Medicine Service/Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Virginia Kaklamani, MD, DSc
Professor
Department of Medicine
University of Texas Health Science Center
San Antonio, Texas

Faculty

Michelle Melisko, MD
Clinical Professor
Department of Medicine
(Hematology/Oncology)
Helen Diller Family Comprehensive
Cancer Center
University of California, San Francisco
San Francisco, California

Jane L. Meisel, MD
Associate Professor
Department of Hematology and
Oncology
Winship Cancer Institute at
Emory University
Atlanta, Georgia

Faculty

Ruth O'Regan, MD
Charles Ayrault Dewey Distinguished Professor of Medicine
Chair, Department of Medicine
Physician-in-Chief, Strong Memorial Hospital
Associate Director of Education and Mentoring
Wilmot Cancer Institute
University of Rochester
Rochester, New York

Ruta Rao, MD
Professor of Medicine
Medical Director
Rush University Cancer Center
Chicago, Illinois

Faculty

Laura M. Spring, MD
Assistant Professor of Medicine
Harvard Medical School
Attending Physician, Medical Oncology (Breast Program)
Massachusetts General Hospital
Boston, Massachusetts

Disclosure of Conflicts of Interest

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Disclosure of Conflicts of Interest

The ***faculty*** reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Joyce O'Shaughnessy, MD, has disclosed that she has received consulting fees from AbbVie, Agendia, Amgen, Aptitude, AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, G1 Therapeutics, Genentech, Immunomedics, Ipsen, Jounce, Lilly, Merck, Myriad, Novartis, Ondonate, Pfizer, Puma, Prime, Roche, Seattle Genetics, and Syndax.

Sara Tolaney, MD, has disclosed that she has received funds for research support (paid to her institution) from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech, Immunomedics/Gilead, Lilly, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics and consulting fees from 4D Pharma, AstraZeneca, Athenex, BeyondSpring, Bristol-Myers Squibb, Chugai, CytomX, Daiichi Sankyo, Eisai, Ellipses Pharma, Genentech, Immunomedics/Gilead, Infinity, Lilly, Mersana, Novartis, OncoPep, OncoSec, OncXerna, Pfizer, Puma, Sanofi, Samsung Bioepsis, Seattle Genetics, Zymeworks, and Zentalis.

Disclosure of Conflicts of Interest

The ***faculty*** reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Adam M. Brufsky, MD, PhD, has disclosed that he has received consultant/advisor/speaker fees from AstraZeneca, Daiichi Sankyo, Lilly, Merck, Novartis, Pfizer, and Roche.

Susan Dent, MD, FRCPC, has no relevant conflicts of interest to report.

Komal Jhaveri, MD, FACP, has disclosed that she has received consultant/advisor/speaker fees from AbbVie, AstraZeneca, Biotheranostics, Blueprint Medicines, Bristol-Myers Squibb, Genentech, Jounce Therapeutics, Lilly Pharmaceuticals, Novartis, Pfizer, Seattle Genetics, Sun Pharma Pvt Ltd, and Taiho Oncology and funds for research support from ADC Therapeutics, AstraZeneca, Clovis Oncology, Debio, Genentech, Immunomedics, Lilly, Merck/VelosBio, Novartis, Novita, Pfizer, Puma, and Zymeworks.

Disclosure of Conflicts of Interest

The ***faculty*** reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Erika P. Hamilton, MD, has disclosed that she has received consultant/advisor/speaker fees from Arcus, Arvinas, AstraZeneca, Black Diamond, Boehringer Ingelheim, CytomX, Daiichi Sankyo, Dantari, Deciphera, Eisai, H3 Biomedicine, iTeos, Janssen, Lilly, Loxom, Merck, Mersana, Novartis, Pfizer, Puma, Relay Therapeutics, Roche/Genentech, Seattle Genetics, and Silverback and funds for research support from Abbvie, Acerta, ADC Therapeutics, Akesobio, Amgen, Aravive, ArQule, Arvinas, AstraZeneca, AtlasMedx, Black Diamond, Boehringer Ingelheim, Clovis Oncology, Compugen, Curis, CytomX, Daiichi Sankyo, Deciphera, eFFECTOR Therapeutics, Ellipses, EMD Serono, Fochon, Fujifilm, GI Therapeutics, Harpoon, H3 Biomedicine, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, InvestisBio, Jacobio, Karyopharm, Leap, Lilly, Lycera, MabSpace, MacroGenics, MedImmune, Merck, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetics, Novartis, Nucana, Olema, OncoMed, Onconova, ORIC, Orinove, Pieris, PharmaMar, Pfizer, Plexxikon, Plonyr, Radius Health, Regeneron, Repertoire Immune Medicines, Rgenix, Roche/Genentech, SeaGen, Sermonix, Shattuck Labs, Silverback, Stem CentRx, Sutro, Syndax, Syros, Taiho, Tapimmune, Tesaro, Treadwell Therapeutics, Verastem, Vincerx Pharma, Zenith Epigenetics, and Zymeworks.

Disclosure of Conflicts of Interest

The ***faculty*** reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Sara Hurvitz, MD, FACP, has disclosed that she has received fees for contracted research from Ambrx, Amgen, Bayer, Cytomx, Daiichi-Sankyo, Dignitana, Genentech/Roche, Gilead, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Orinove, Phoenix Molecular Designs, Pfizer, Pieris, Puma, Radius, Sanofi, Seattle Genetics/Seagen, and Zymeworks.

Virginia Kaklamani, MD, DSc, has disclosed that she has received consultant/advisor/speaker fees from AstraZeneca, Genentech, Gilead, Novartis, Pfizer, Puma, and Seagen.

Jane L. Meisel, MD, has disclosed that she has received consulting fees from AstraZeneca, Genentech, GlaxoSmithKline, Lilly, Pfizer, Sanofi Genzyme, and Seagen.

Michelle Melisko, MD, has disclosed that she has received consultant/advisor/speaker fees from Biotheranostics and funds for research support from Novartis, OBI Pharmaceuticals, Puma, and Seattle Genetics.

Disclosure of Conflicts of Interest

The ***faculty*** reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Ruth O'Regan, MD, has disclosed that she has received consultant/advisor/speaker from Biotheranostics, Genentech, Genomic Health, Immunomedics, Lilly, MacroGenics, Novartis, Pfizer, and Puma.

Ruta Rao, MD, has disclosed that she has received consulting fees from Genentech, Novartis, and Sanofi.

Laura M. Spring, MD, has disclosed that she has received consulting fees from Novartis and Puma.

Staff Disclosures

The ***planners/managers*** reported the following relationships:

Kemi Obajimi, PhD; Kristen Rosenthal, PhD; Gordon Kelley; Timothy A. Quill, PhD; Krista Marcello; Kelly G. Brandt, PharmD, BCOP, BCPS; and **Kevin Obholz, PhD,** have no relevant conflicts of interest to report.

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN has received speaker fees from BMS, Lilly, Sanofi, Regeneron, Gilead, Morphosys, Pfizer, AstraZeneca and DSI.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Goal

The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to optimally assess patients with HR-positive/HER2-negative early breast cancer for Ki67 and accurately report, interpret, and apply results of the testing to optimal therapy selection.

Target Audience

This program is intended for oncologists, pathologists, histotechnologists, pharmacists, oncology nurses, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

At the conclusion of this activity, learners should be able to:

- Incorporate the evidence on the current use of Ki67 as a predictive and prognostic biomarker into clinical practice
- Evaluate the clinical validity, utility, and differences among Ki67 assessment techniques
- Integrate best practices for Ki67 testing methodology, standardization, and reporting
- Identify patients with high-risk features who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting
- Foster collaborative discussions and workflows among oncologists, pathologists, and the multidisciplinary team on recent clinical evidence to guide personalized treatment planning for HR-positive/HER2-negative early breast cancer
- Identify patients with HR-positive/HER2-negative early breast cancer that expresses Ki67 who may be eligible for ongoing clinical trials

Accreditation Information

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medial Education

CCO designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

UAN Live Meeting: JA4008176-0000-22-006-L01-P

UAN Virtual: JA4008176-0000-22-007-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Designation of Credit

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Activity is 1.0 contact hour.

Please refer to this card for instructions to receive CE credit and for additional resources

Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer:

Education and Resources for the Oncology and Pathology Healthcare Teams

EVALUATION AND REQUEST FOR CREDIT

Below are instructions for evaluating and requesting credit for the CME/CPE/CE-certified live meeting.

- Go to **www.clinicaloptions.com/event/Ki67ASCP22Eval** to access the online evaluation and credit request system. You can use any computer or Internet interactive device or scan the QR code to complete the evaluation and credit request process.
- View and print your certificate upon completion of the online evaluation.

You have **30 days** before the link expires to complete the evaluation details and print your certificate.

CLINICAL RESOURCES

Download slidesets from the live event
(available at: **www.clinicaloptions.com/event/Ki67ASCP22Slides**)

On-demand webcast
(available at: **www.clinicaloptions.com/event/Ki67ASCP22Webcast**)

ClinicalThought
(available at: **www.clinicaloptions.com/event/Ki67ASCP22CCT**)

CCO
powered by cea

General Information

- Slides from today's presentation are now available on the CCO website

www.clinicaloptions.com/event/Ki67ASCP22Slides

Go Online for More CCO/ASCP Coverage of Breast Cancer!

CME/CPE/CE-certified on-demand webcasts of 2 live workshops (*coming soon*)

Downloadable slideset with slides from today's presentation, and updated throughout the course of the live meeting series (*available now*)

CME/CMLE-certified podcast (*coming soon*)

Downloadable clinical resource (*coming soon*)

Expert commentaries (*coming soon*)

clinicaloptions.com/oncology

ascp.org/content/learning/breast cancer

ASCP STRONGERTOGETHER

CCO